NIH study finds omalizumab relieves seasonal asthma attacks in youth – 2
Narrator: This is NIH Health Matters. I’m Joe Balintfy. One aim of a recent study has been to find out if the addition of the drug omalizumab could reduce asthma symptoms in inner-city children and youth age 6 to 20. And it does, says Dr. Alkis Togias at the National Institute of Allergy and Infectious Diseases.
Dr. Togias: For us, this study was not only a proof of concept that allergy is a very important factor in asthma in this particular group of children, but it opened up a path of developing perhaps new strategies of using this medication.
Narrator: Patients in the study who received omalizumab had a 75 percent reduction in hospitalizations. For details, visit www.niaid.nih.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.